222530-29-2

Basic information

• Product Name: Cis Methyl 3-aMinocyclopentanecarboxylate hydrochloride
• Synonyms: Cis Methyl 3-aMinocyclopentanecarboxylate hydrochloride;CIS-METHYL 3-AMINOCYCLOPENTANECARBOXYLATE HCL
• CAS NO: 222530-29-2
• Molecular Formula: C7H14ClNO2
• Molecular Weight: 179.64456
• Mol File: 222530-29-2.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Cis Methyl 3-aMinocyclopentanecarboxylate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Cis Methyl 3-aMinocyclopentanecarboxylate hydrochloride(222530-29-2)
• EPA Substance Registry System: Cis Methyl 3-aMinocyclopentanecarboxylate hydrochloride(222530-29-2)

Safety Data

• Hazardous Substances Data: 222530-29-2(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 71830-07-4 (1S,3R)-3-aminocyclopentanecarboxylic acid 
• 75-36-5 acetyl chloride 
• 329910-39-6 (1S,3S)-1-(tert-butoxycarbonylamino)cyclopentane-3-carboxylic acid methyl ester 
• 489446-72-2 (1R,3R)-3-tert-butoxycarbonylaminocyclopentanecarboxylic acid methyl ester 
• 130931-83-8 (1S,4R)-2-azabicyclo[2,2,1]hept-5-en-3-one 
• 71830-08-5 (1R,3S)-3-aminocyclopentanecarboxylic acid 
• 79200-56-9 (-)-2-azabicyclo[2.2.1]hept-5-en-3-one 
• 134003-03-5 (+)-2-Azabicyclo<2.2.1>heptan-3-one 
• 147698-14-4 (1S,4R)-N-(9-Phenylfluoren-9-yl)-2-azabicyclo<2.2.1>heptan-3-one 
• 1203306-05-1 (1R,3S)-3-aminocyclopentanecarboxylic acid hydrochloride 

Relevant articles and documents

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF

Provided herein are methods for rational design of nicotine haptens. More particularly, provided herein are methods for designing, selecting, and synthesizing nicotine haptens and nicotine hapten conjugates. Also provided herein are novel nicotine haptens and methods for using nicotine haptens to treat nicotine addiction.

Tetrahydroquinazolinone Derivatives as PARP Inhibitors

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.